Key Points
- Liposomal NR wraps nicotinamide riboside in phospholipid spheres intended to improve gut survival and absorption — a technology with good logic but limited human-specific validation for this ingredient.
- Standard oral NR is already well-absorbed in humans, with multiple RCTs showing reliable NAD+ elevation at 250–1,000 mg/day — making the baseline the liposomal form must beat higher than for poorly absorbed nutrients.
- No peer-reviewed, published human RCT has directly compared oral liposomal NR to standard NR capsules for NAD+ elevation; the claimed absorption advantage is not yet verified in humans.
Short answer: the theoretical case for liposomal NR is reasonable, but it currently outpaces the human evidence — standard oral NR-Cl already reliably raises NAD+ in humans, and no human trial has confirmed that liposomal delivery does so more effectively. Whether the premium price is justified depends on what you're optimizing for and how much you weight mechanism plausibility vs. direct human proof.
What is liposomal delivery and why does it matter for some nutrients?
Liposomes are tiny spheres made of phospholipid bilayers — the same material that makes up cell membranes. When a nutrient is encapsulated inside a liposome, the idea is that the lipid shell protects it from degradation in the stomach, allows it to be absorbed more efficiently through the gut wall via endocytosis (cells essentially engulfing the lipid sphere), and potentially delivers the payload more directly to target tissues.
Liposomal technology has legitimate pharmaceutical applications — certain chemotherapy drugs and antifungal medications use liposomal formulations specifically because the delivery improvement is clinically meaningful and well-documented. The supplement industry has applied the same concept to nutrients like vitamin C (where some data supports improved absorption), glutathione, and now NR and NMN.
The key question is whether a given nutrient needs this help — and this is where NR is genuinely different from, say, poorly water-soluble nutrients that struggle to cross the gut wall on their own.
How well-absorbed is standard NR already?
NR has a well-established oral bioavailability profile from multiple human trials. The 2016 Trammell et al. pharmacokinetic study (Nature Communications, PMCID PMC5062546) showed dose-dependent blood NAD+ increases within hours of oral doses of 100, 300, and 1,000 mg, in healthy humans. The 8-week Conze et al. RCT (Scientific Reports, PMCID PMC6611812) demonstrated 22–142% whole-blood NAD+ increases at 100–1,000 mg/day with standard NR-Cl capsules. The Dellinger et al. RCT (npj Aging, PMCID PMC5701244) showed ~40% NAD+ increase at recommended doses in 120 healthy adults aged 60–80.
In other words: the baseline for standard oral NR is already good. For many nutrients marketed in liposomal form, the comparison point is a poorly absorbed compound. NR doesn't fit that description. This doesn't mean liposomal NR can't outperform standard NR — it means the bar it has to clear is higher, and that bar matters when evaluating whether the evidence justifies the premium.
What the evidence actually shows
Animal model (2024, ScienceDirect) — A Chinese research team encapsulated NR-Cl in optimized liposomes and administered them by IV injection in a mouse cerebral ischemia model. They found improved brain NAD+ delivery compared to oral NR-solution, which they attributed to the liposome's ability to partially cross the blood-brain barrier when delivered intravenously. This is interesting preclinical data, but it used IV administration and a specific disease model — neither translates directly to an oral supplement in healthy adults.
The liposomal NMN comparison (not NR, but relevant context) — A 2025 double-blind human trial compared liposomal NMN to standard NMN and found that liposomal NMN raised blood NAD+ by approximately 84% vs. a lower increase in the standard-NMN group. This is the closest direct comparison data for liposomal NAD+ precursors in humans — but it tested NMN, not NR, and was funded by a supplier with a commercial interest in liposomal NMN. It also doesn't answer the NR-specific question.
The honest counterweight: A 2025 ConsumerLab update flagged that some "liposomal" supplements don't actually deliver what their labels proclaim — liposomal encapsulation is difficult to verify without specialized testing, and some products labeled liposomal may contain minimal or unstable liposomes. There is also a hypothesis that liposomes may actually interfere with gut microbiome conversion of NR to nicotinic acid (NA), which some researchers believe is a primary pathway by which NR raises circulating NAD+. If that hypothesis is correct, encapsulating NR could theoretically reduce, not enhance, its effectiveness — though this remains speculative.
| Factor | Standard NR Capsule | Liposomal NR |
|---|---|---|
| Human RCT evidence | Multiple (Trammell 2016, Dellinger 2017, Conze 2019) | None published (head-to-head vs standard NR) |
| Blood NAD+ elevation | Reliable; 22–142% at 100–1,000 mg/day | Plausible but unconfirmed in humans vs standard |
| Price point | Lower to moderate | Typically higher (30–100% premium) |
| Label accuracy risks | High (87% category failure rate) | High + additional liposome quality verification challenge |
| Brain NAD+ delivery | Indirect; via peripheral NAD+ | Animal IV data promising; oral human data absent |
What liposomal NR won't do (that some marketing implies)
Liposomal NR has not been shown to produce better functional outcomes (energy, cognition, aging biomarkers) than standard NR in any published human trial. "Better absorption" in a theoretical sense does not automatically translate to better clinical effects, particularly when the baseline compound already absorbs reasonably well. No liposomal NR formulation currently has the breadth of human evidence behind it that standard NR-Cl does.
If you are interested in NR primarily because of the trial evidence — blood NAD+ elevation, arterial stiffness signals, the long-COVID cognitive data — that evidence was generated with standard NR-Cl formulations, not liposomal ones. See our NR deep dive and our NR buyer's guide for more on what the existing evidence base actually supports. See a doctor if your reason for considering NR relates to neurological symptoms, cardiovascular concerns, or persistent fatigue — those are medical questions before they are supplement questions.
What users report
In NAD+ and longevity forums, liposomal NR generates divided opinion. Some users report preferring the softer capsule format (many liposomal NR products use softgels) and describe subjective energy or clarity improvements, though these are self-reported and uncontrolled. Others report no difference versus standard NR at similar doses. A recurring theme is frustration with premium pricing relative to unclear evidence of superiority. Anecdotal reports are not evidence, but the pattern is consistent with what the research would predict: if standard NR already raises your NAD+, adding liposomal delivery may not produce a detectable experiential difference.
FAQ
Is liposomal NR worth the extra cost?
That depends on your framework. If you value mechanistic plausibility and want to potentially maximize tissue delivery, liposomal NR is a reasonable experiment — but you're paying for a hypothesis, not a proven improvement over standard NR. If you prioritize evidence-backed certainty, standard NR-Cl has the cleaner trial record.
Do liposomal supplements degrade faster?
Liposome stability is a real concern. Phospholipid shells can oxidize or break down during storage, especially at high temperatures. Products in softgels kept refrigerated after opening tend to be more stable. This is an additional quality-verification challenge on top of the already-difficult NR potency verification problem.
Is the "71% better absorption" claim for liposomal NR verified?
No. This figure, which appears in some supplement marketing, appears to derive from an internal or commissioned study, not an independent peer-reviewed head-to-head human trial comparing oral liposomal NR to oral standard NR. Treat it with appropriate skepticism until confirmed by independent research.
What about liposomal NAD+ directly — does that absorb better?
NAD+ itself is a large molecule that is not efficiently absorbed intact through the gut wall; the body must break it down to NR or NMN before uptake. Liposomal NAD+ attempts to circumvent this via endocytosis. Early data exists but is limited — see our article on liposomal NAD+ for the full breakdown on that related question.
From Nuvirox
Why we formulated NAD+ Restore
- 500 mg Nicotinamide Riboside Chloride per serving — the form used in published human trials, within the dose range the evidence supports
- Polyphenols studied alongside NAD+ pathways for cellular health support: 150 mg trans-resveratrol (Japanese Knotweed) and 50 mg quercetin (Sophora japonica)
- 10 mg galactomannans from fenugreek to support absorption
- 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should
The bottom line
Liposomal NR is a scientifically plausible format with a clear theoretical rationale — but the human evidence hasn't caught up to the marketing yet. Standard oral NR-Cl is already demonstrably absorbed and has the RCT track record. Until a well-designed, independent human trial shows that liposomal NR produces meaningfully higher NAD+ levels or better functional outcomes than matched doses of standard NR, the case for paying a premium remains a bet on mechanism rather than proof. That may be a reasonable bet depending on your goals — but it should be a conscious one.
- Trammell SAJ et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016;7:12948. PMCID: PMC5062546. doi:10.1038/ncomms12948
- Dellinger RW et al. Repeat dose NRPT increases NAD+ levels in humans safely and sustainably. npj Aging Mech Dis. 2017;3:17. PMCID: PMC5701244. doi:10.1038/s41514-017-0016-9
- Conze D et al. Safety and Metabolism of Long-term Administration of NIAGEN in Healthy Overweight Adults. Sci Rep. 2019;9:9772. PMCID: PMC6611812. doi:10.1038/s41598-019-46120-z
- Liu X et al. Liposome-based loading enhances the distribution of nicotinamide riboside chloride into the brain and its neuroprotective effects in cerebral ischemic mice. J Nanobiotechnology. 2024. doi:10.1016/j.jcjb.2024.000184
- Freeberg KA et al. Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions. J Gerontol A Biol Sci Med Sci. 2023;78(12):2435-2448. PMID: 37068054. doi:10.1093/gerona/glad106
- ConsumerLab.com. NAD Booster Supplements Review. Updated 2026. (Notes: some liposomal supplements may not deliver what labels proclaim.)
- Mehmel M et al. Nicotinamide Riboside — The Current State of Research and Therapeutic Uses. Nutrients. 2020;12(6):1616. PMCID: PMC7352172. doi:10.3390/nu12061616
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.